These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9545668)

  • 21. In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus.
    Toyokawa M; Asari S; Nishi I; Horikawa M; Tsukamoto H; Sunada A; Ueda A; Iwatani Y
    J Chemother; 2003 Feb; 15(1):31-6. PubMed ID: 12678411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacokinetic, bacteriological and clinical studies on cefozopran in the pediatric field].
    Motohiro T; Handa S; Yamada S; Sasaki H; Oki S; Yoshinaga Y; Oda K; Aramaki M; Sakata Y; Yamashita F
    Jpn J Antibiot; 1994 Nov; 47(11):1589-611. PubMed ID: 7853690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2004)].
    Goto H; Takeda H; Kawai S; Watanabe T; Okazaki M; Shimada K; Nakano K; Yokouchi H; Ikemoto H; Mori T; Igari J; Oguri T; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Kudo K; Kobayashi N; Tanaka T; Sumitomo M; Matsushima T; Oka M; Niki Y; Suga M; Tosaka M; Kohno S; Hirakata Y; Kondou A; Matsuda J; Nakano M; Nasu M; Hiramatsu K; Oikawa S
    Jpn J Antibiot; 2006 Oct; 59(5):323-54. PubMed ID: 17180803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro combination effect of pazufloxacin with various antibiotics against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus].
    Maekawa M; Takahashi K; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):440-5. PubMed ID: 12378872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined effects of arbekacin with other antibiotics against methicillin-resistant Staphylococcus aureus. IV. Combined effects of arbekacin with cefmetazole or flomoxef].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1992 Oct; 45(10):1312-8. PubMed ID: 1479683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1998)].
    Ikemoto H; Arakawa M; Gejyo F; Igarashi K; Mori T; Okada M; Ozaki K; Igari J; Aoki N; Oguri T; Kitamura N; Terai T; Sekine O; Suzuki Y; Inoue H; Nakadate T; Karasawa Y; Ito C; Yoshida T; Nakata K; Nakatani T; Ohno I; Okada S; Inagawa H; Kudo K; Kobayashi N; Ando M; Suga M; Sato K; Kondo T; Tosaka M; Kobayashi H; Kawai S; Takayasu S; Kohno S; Tomono K; Shimada K; Nakano K; Miyazaki Y; Izumikawa K; Yamaguchi T; Mochida C; Yokouchi H; Ito A; Sumitomo M; Nasu M; Nagai H; Yamasaki T; Matsushima T; Nakano T
    Jpn J Antibiot; 2000 May; 53(5):261-98. PubMed ID: 10923284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2001). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Watanabe K; Kobayashi Y; Matsukawa M; Uchida H; Kunishima Y; Hirose T; Matsuda S; Sato S; Shigeta S; Fujime M; Fujita K; Yamaguti O; Ogihara M; Ishibashi K; Igari J; Takahashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Furuya N; Kashitani F; Murai M; Ooe H; Nishikawa M; Kumon H; Monden K; Oka T; Kitamura M; Kohno S; Tomono K; Miyazaki Y; Matsuoka Y; Fukuhara Y; Hirakata Y; Aoki S
    Jpn J Antibiot; 2003 Oct; 56(5):396-423. PubMed ID: 14692378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bacteriological evaluation of combined effects of vancomycin and beta-lactams. I. Results against methicillin-resistant Staphylococcus aureus].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1993 Nov; 46(11):939-45. PubMed ID: 8309069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--I. Gram-positive bacteria].
    Suzuki Y; Nishinari C; Endo H; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Aug; 56(4):294-308. PubMed ID: 14567254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
    Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
    Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Combined effects of arbekacin with other antibiotics against methicillin-resistant Staphylococcus aureus. II. The combined effect of arbekacin with imipenem or cefminox].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1992 Aug; 45(8):958-64. PubMed ID: 1433902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2003). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Hirose T; Sato S; Shigeta S; Fujime M; Fujita K; Yamaguti O; Ishibashi K; Igari J; Suzutani T; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Furuya N; Murai M; Deguchi T; Ishihara S; Ooe H; Matsumoto T; Takahashi K; Nishikawa M; Naito S; Egashira T; Konishi T; Oka T; Kitamura M; Kohno S; Fukuhara Y; Hirakata Y; Kondo A; Matsuda J; Nakano M; Kamidono S; Suzuki Y; Arakawa S; Kumon H; Monden K
    Jpn J Antibiot; 2005 Dec; 58(6):518-43. PubMed ID: 16521344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). III. Secular changes in susceptibility].
    Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Shigeta S; Yamaguchi O; Ishibashi K; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Muratani T; Naito S; Egashira T; Konishi T; Kohno S; Hirakata Y; Kondo A; Matsuda J; Nakano M
    Jpn J Antibiot; 2006 Aug; 59(4):217-315. PubMed ID: 17111595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1993)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Feb; 49(2):107-43. PubMed ID: 8721076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The resistance of recent clinical isolates against isepamycin, other aminoglycosides and injectable beta-lactams].
    O'Hara K; Nakamura A; Sawai T; Hosino K; Iwai Y; Nakamura S; Seto I
    Jpn J Antibiot; 2000 Jan; 53(1):46-59. PubMed ID: 10709145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1991). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Oct; 48(10):1394-421. PubMed ID: 8544337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacokinetic and clinical studies on cefozopran in the field of pediatrics].
    Kaino Y; Kida K; Matsuda H
    Jpn J Antibiot; 1994 Nov; 47(11):1565-75. PubMed ID: 7853687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The antimicrobial activity in vitro of cefpirome and 6 other beta-lactam antibacterial agents against clinical isolates.
    Yoshimura H; Kosaka Y; Hayashi T; Kawahara S
    Jpn J Antibiot; 1993 Oct; 46(10):877-83. PubMed ID: 8254889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of arbekacin, alone and in combination, against methicillin-resistant Staphylococcus aureus.
    Kono K; Takeda S; Tatara I; Arakawa K
    Jpn J Antibiot; 1994 Jun; 47(6):710-9. PubMed ID: 8072179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.